Supercharge Your Innovation With Domain-Expert AI Agents!

Application of compound in preparation of medicine for treating idiopathic pulmonary fibrosis

A technology for pulmonary fibrosis and idiopathic disease, applied in the field of biomedicine, can solve problems such as irreversible disease progression, achieve the effect of reducing lung collagen content and improving forced vital capacity

Pending Publication Date: 2021-12-24
TIANJIN JIKUN MEDICAL TECH CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Only pirfenidone and nintedanib are currently approved effective drugs for the treatment of IPF. Although these drugs can delay the decline in lung function, they cannot reverse the progression of the disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of compound in preparation of medicine for treating idiopathic pulmonary fibrosis
  • Application of compound in preparation of medicine for treating idiopathic pulmonary fibrosis
  • Application of compound in preparation of medicine for treating idiopathic pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] Example 1: Preliminary drug efficacy evaluation of baricitinib and Duweilib

[0059]1. Animal model preparation: The idiopathic pneumonia model using bleomycin is currently the most used idiopathic pulmonary fibrosis model. Male C57BL / 6J wild-type mice (8-10 weeks old) were anesthetized by intraperitoneal injection of 0.5ml / 100g (body weight) with a mass volume concentration of 10% chloral hydrate, and intratracheal invasive injection of 2U / kg bleomycin. The specific implementation method is as follows: after the mouse is anesthetized, weigh and record, fix the mouse on the operating table, disinfect the neck with 70% alcohol, use a scalpel to cut a vertical wound of about 1 cm in the neck of the mouse, and use micro tweezers to separate The tissue exposed the trachea, and the syringe was pierced into the trachea through the gap between the tracheal cartilage rings toward the heart, and then slowly injected with a volume of bleomycin saline solution corresponding to i...

Embodiment 2

[0066] Example 2: Preliminary efficacy evaluation of clavudine and favipiravir

[0067] 1. Animal model preparation: the same as the modeling method in Example 1.

[0068] 2. Grouping of mice: divided into 5 groups, namely normal saline group, bleomycin group, positive drug group, clavudine group and favipiravir group, with 7 mice in each group.

[0069] 3. Group administration of mice:

[0070] The normal saline group is a sham operation group that injects normal saline (0.9%NaCl) into the mouse trachea, and the normal saline group is treated with the 7th to 14th day of the sham operation, and the mice of the administration group are intragastrically administered every day (referring to the clavudine group and Favipiravir group) the same volume of normal saline (0.9% NaCl) as a control;

[0071] The mice in the bleomycin group, the positive drug group, the clavudine group, and the favipiravir group were all established by intratracheal invasive injection of 2U / kg bleomycin;...

Embodiment 3

[0074] Example 3: Preliminary efficacy evaluation of ozanimod, enzalutamide and lenalidomide

[0075] 1. Animal model preparation: the same as the modeling method in Example 1.

[0076] 2. Grouping of mice: divided into 6 groups, namely normal saline group, bleomycin group, positive drug group, ozanimod group, enzalutamide group, lenalidomide group, 7 groups per group mice.

[0077] 3. Group administration of mice:

[0078] The normal saline group is a sham operation group that injects normal saline (0.9% NaCl) into the mouse trachea, and the normal saline group is treated with sham operation on the 7th-14th day, and the mice of the administration group (referring to ozanimod group, enzalutamide group and lenalidomide group) with the same volume of normal saline (0.9% NaCl) as a control;

[0079] The mice in the bleomycin group, the positive drug group, the ozanimod group, the lenalidomide group, and the enzalutamide group were all made by intratracheal invasive injection o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of a compound in preparation of a medicine for treating idiopathic pulmonary fibrosis. The compound is selected from one or more of baricitinib, duvirib, clevudine, favipiravir, lenalidomide, entrectinib, fetratinib or pharmaceutically acceptable salts, esters and hydrates of the baricitinib, the duvirib, the clevudine, the favipiravir, the lenalidomide, the entrectinib and the fetratinib. In the application, the baricitinib, the duvirib, the clavudine, the favipiravir, the lenalidomide, the entrectinib, the fetratinib or the pharmaceutically acceptable salts, esters and hydrates thereof have good effects on the idiopathic pulmonary fibrosis, have no adverse reaction, the forced vital capacity, inspiration airway resistance, expiration airway resistance and dynamic compliance of a patient with the idiopathic pulmonary fibrosis can be improved; the pulmonary hydroxyproline content of the patient with the idiopathic pulmonary fibrosis is reduced; the pulmonary fibrosis area is reduced or the increase of the pulmonary fibrosis area is prevented.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of compounds in the preparation of medicines for treating idiopathic pulmonary fibrosis. Background technique [0002] With the aggravation of environmental pollution, the incidence of lung diseases continues to rise. Pulmonary fibrosis (PF) is characterized by persistent damage to the alveoli, proliferation of fibroblasts, and deposition of a large amount of extracellular matrix (ECM), resulting in varying degrees of inflammation and fibrosis in the alveoli and interstitium. A disease that causes structural destruction of the lungs and respiratory failure. [0003] Idiopathic pulmonary fibrosis (IPF) is different from pulmonary fibrosis of known cause and is the most common and severe chronic interstitial lung disease of unknown etiology. IPF originates from recurrent or persistent Abnormal repair of alveolar epithelial injury. Clinically, IPF presents as progressiv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/519A61K31/52A61K31/4965A61K31/7072A61K31/454A61K31/496A61K31/506A61P11/00
CPCA61K31/7072A61P11/00Y02A50/30
Inventor 周红刚杨诚张亮李建伦东超李霄鹤
Owner TIANJIN JIKUN MEDICAL TECH CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com